DelveInsight has launched a new report on “Duchenne Muscular Dystrophy (DMD) Market Insights, Epidemiology, and Market Forecast-2032”. 

DelveInsight’s “Duchenne Muscular Dystrophy (DMD) – Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Duchenne Muscular Dystrophy (DMD), historical and forecasted epidemiology as well as the Duchenne Muscular Dystrophy (DMD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. 

Some of the key facts of the Duchenne Muscular Dystrophy (DMD) Market Report:

• According to the National Organization for Rare Diseases (NORD), DMD is the most common childhood-onset form of muscular dystrophy and affects males almost exclusively 
• The prevalence of Duchenne Muscular Dystrophy is estimated to be 1/3,500 live male births, and the age of onset is usually between 3–5 years 
• The total diagnosed prevalent population of DMD in the 7 major markets was 27,813 in 2018, wherein the diagnosed prevalent cases of DMD patients in the United States were 16,941 
• As per the studies, females are rarely affected by Duchenne Muscular Dystrophy
• The maximum number of total diagnosed prevalent cases of DMD patients were in the age group 8–13 and 14–19 in the United States, which were 4,786 and 4,742 cases 

Request a sample for the Report: https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-market

Key benefits of the report:

1. Duchenne Muscular Dystrophy (DMD) market report covers a descriptive overview and comprehensive insight of the Duchenne Muscular Dystrophy (DMD) Epidemiology and Duchenne Muscular Dystrophy (DMD)  market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. The Duchenne Muscular Dystrophy (DMD) market report provides insights on the current and emerging therapies.
3. Duchenne Muscular Dystrophy (DMD) market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. The Duchenne Muscular Dystrophy (DMD) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Duchenne Muscular Dystrophy (DMD) market. 

Epidemiology Segmentation of Duchenne Muscular Dystrophy (DMD) –

• Age-specific Diagnosed Prevalent Population of Duchenne Muscular Dystrophy (DMD) in the 7MM [2019-2032] 
• Total Diagnosed Prevalent Population of Duchenne Muscular Dystrophy (DMD) in the 7MM [2019-2032] 
• Mutation-specific Diagnosed Prevalent Population of Duchenne Muscular Dystrophy (DMD) in the 7MM [2019-2032]
• Ambulatory and non-ambulatory Diagnosed Prevalent Population of Duchenne Muscular Dystrophy (DMD) in the 7MM [2019-2032]
• Diagnosed Prevalence of Associated Comorbidities in Duchenne Muscular Dystrophy (DMD) in the 7MM [2019-2032] 

Got queries? Click here to know more about the Duchenne Muscular Dystrophy (DMD) Market Landscape 

Duchenne Muscular Dystrophy (DMD) Overview: 

Duchenne muscular dystrophy (DMD) is the most common form of muscular dystrophy in children. It is an agenetic disorder characterized by progressive muscle degeneration and weakness and is one of nine types of muscular dystrophy. 

DMD is caused by an absence of dystrophin, a protein that helps keep muscle cells intact. Symptom onset is in early childhood, usually between ages 3–5. The disease primarily affects boys, but in rare cases, it can affect girls. DMD is inherited in an X-linked pattern because the gene that can carry a DMD-causing mutation is on the X chromosome. It is caused by mutations of the DMD gene, leading to progressive muscle weakness, loss of independent ambulation by early teens, and premature death due to cardiorespiratory complications. 

Duchenne Muscular Dystrophy (DMD) Symptoms: 

The symptoms of Duchenne muscular dystrophy include –

1. Frequent Falls
2. Larger calf muscles
3. Waddling gait
4. Muscle pain and stiffness
5. Waddling gait
6. Trouble running and jumping 

Duchenne Muscular Dystrophy (DMD) Market  

The dynamics of the Duchenne Muscular Dystrophy (DMD) market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Vamorolone, Givinostat, and others during the forecasted period 2019-2032. 

Learn more by requesting for sample @Duchenne Muscular Dystrophy (DMD) Market Landscape  

Duchenne Muscular Dystrophy (DMD) Pipeline Therapies:

• Vamorolone
• Givinostat
• Viltolarsen
• EDG-5506  

Duchenne Muscular Dystrophy (DMD) Pipeline Therapies:

• NS Pharma
• Sarepta Therapeutics
• ReveraGen BioPharma
• Edgewise Therapeutics

Table of Contents 

1. Duchenne Muscular Dystrophy (DMD) Market Report Introduction

2. Executive Summary

3. SWOT analysis

4. Duchenne Muscular Dystrophy (DMD) Patient Share (%) Overview at a Glance

5. Duchenne Muscular Dystrophy (DMD) Market Overview at a Glance

6. Duchenne Muscular Dystrophy (DMD) Disease Background and Overview

7. Duchenne Muscular Dystrophy (DMD) Epidemiology and Patient Population

8. Country-Specific Patient Population of Duchenne Muscular Dystrophy (DMD) 

9. Duchenne Muscular Dystrophy (DMD) Current Treatment and Medical Practices

10. Duchenne Muscular Dystrophy (DMD) Unmet Needs

11. Duchenne Muscular Dystrophy (DMD) Emerging Therapies

12. Duchenne Muscular Dystrophy (DMD) Market Outlook

13. Country-Wise Duchenne Muscular Dystrophy (DMD) Market Analysis (2018–2030)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Duchenne Muscular Dystrophy (DMD) Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Click here to read more about Duchenne Muscular Dystrophy (DMD) Market Outlook 2032

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com